**Table S2: Components of table 1**

|  |  |  |
| --- | --- | --- |
|  |  |  |
| **Baseline demographic characteristics (measured on index date)** |
|  |  |  |
| Age  |  |  |  |
|  |  |  |
| Gender  |  |  |  |
|  |  |  |
| Neighborhood income quintile (based on location of residence on index date) |
|  |  |  |
| Rural or urban residence (rural community defined as community with <=10,000 residents) |
|  |  |  |
| **Health care utilization in preceding yeara (count only one OHIP claim per person per day)**  |
|  |  |  |
| Number of inpatient hospital admissions  |
|  |  |  |
| Number of days in hospital  |
|  |  |  |
| Number of unplanned ED visits  |
|  |  |  |
| Number of primary care physician visits  |
|  |  |  |
| Number of physician Specialist visits  |
|  |  |  |
| **ADHD treatment factors in 180 days prior to index date (identify prescription by DIN from ODB)** |
|  |  |  |
| Amphetamine  |  |  |
|  |  |  |
| Atomoxetine  |  |
|  |  |  |
| Methylphenidate  |  |
|  |  |  |
| **Comorbidities (in the preceding 5 years)** |
|  |  |  |
| Johns Hopkins Aggregated Clinical Groups (ADG) Score (0-4, 5-9, 10-14, 15-19, 20+) |
|  |  |  |
| **Drug utilization in preceding yeara (identify prescription by DIN from ODB)** |
|  |  |  |
| Corticosteroids  |  |
|  |  |  |
| Insulin |  |
|  |  |  |
| Oseltamivir  |  |
|  |  |  |
| Anticonvulsants  | Fosphenytoin, Oxcarbazepine, Phenytoin, Carbamazepine, Ethosuximide, Felbamate, Gabapentin, Levetiracetam, Methsuximide, Pregabalin, Topiramate, Vigabatrin |
|  |  |  |
| Antidepressants  | Amitriptyline, Amoxapine, Bupropion, Citalopram, Clomipramine, Desipramine, Desvenlafaxine, Doxepin, Duloxetine, Escitalopram, Fluoxetine, Fluvoxamine, Imipramine, Maprotiline, Mirtazapine, Nefazodone, Nortriptyline, Paroxetine Protriptyline, Reboxetine, Sertraline, Trazodone, Trimipramine, Venlafaxine hcl, Isocarboxazid, Phenelzine, Tranylcypromine Moclobemide |
|  |  |  |
| Antipsychotics  | Aripiprazole, Asenapine, Chlormezanone, Chlorpromazine, Chlorprothixene, Clozapine, Droperidol, Flupenthixol, Fluspirilene, Haloperidol, Loxapine, Mesoridazine, Methotrimeprazine, Olanzapine, Paliperidone, PericiazinePerphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine, Quetiapine, Remoxipride, Risperidone, Sulpiride, Thiopropazate, Thioproperazine, Thioridazine, Thiothixene, Trifluoperazine, Ziprasidone Zuclopenthixol. |
|  |  |  |
| Benzodiapines | Alprazolam, Bromazepam, Chlordiazepoxide, Clonazepam Clorazepate, Diazepam, Estazolam, Flumazenil, Flurazepam, Ketazolam, Lorazepam, Midazolam, Nitrazepam, Oxazepam, Temazepam, Triazolam, Zaleplon, Zopiclone |
|  |  |  |
| Opioids | Codeine, Dextropropoxyphene, Fentanyl, Hydromorphone, Levorphanol, Meperidine, Morphine, Opium, Oxycodone, Pentazocine, Proproxyphene |
|  |  |  |
| **Individual comorbidity definitions (in the preceding 5 years)** |
|  |  |  |
| Diabetes mellitus  | Defined as diagnosis date in Ontario Diabetes Database that precedes the index date |
|  |  |  |
|  | **ICD9** | **ICD10** | **OHIP** |
| Affective disorder  | 296 | F30, F31, F32.2, F32.3, F32.8, F33, F34.8, 34.9, F38, F39 | 296  |
|  |  |  |
| Anxiety and sleep disorder  | 300 | F32.0, F34.1, F40-42, F44, F45.0-45.2, F48, F68.0, F99 | 300 |
|  |  |  |
| Other mental health disorder  | 301, 302.2-302.9, 304.0-304.6, 304.9, 305.1-305.7, 305.9, 306.4, 306.5, 306.8, 306.9, 307, 308.3, 308.9, 309.0, 309.2, 309.8, 310.1, 310.2, 310.8, 310.9, 311.0, 312.0-312.3, 312.8, 312.9, 313.0, 313.2, 313.3, 313.8, 313.9, 314.0, 314.2, 314.8, 314.9, 315, 316.0 | F06.7, F07, F10, F11.1, F11.2, F12.1, F12.2, F13.1, F13.2, F14.1, F14.3, F15.1, F15.2, F16.1, F16.2, F17.1, F17.2, F18.1, F18.2 F19.1, F19.2, F32.9, F43, F45.3, F45.4, F45.8, F45.9, F50, F51, F52, F53.0, F54-F59, F60-F66, F68.1, F68.8, F69, F80-F83, F88-F95, F98, G31.2, G44.2, G62.1, G72.1,I42.6, K29.2, K70.1,K70.4, K70.9, K86.0, R78.0, T51.0, Y15, Y91, Z50.2, Z71.4, Z86.40 | 291, 301, 302, 303, 304.0-304.9, 305.0-305.9, 306-316 |
|  |  |  |
| Miscellaneous illnesses associated with psychosis | 780.3, 345, 710.0, 2751 | R56.0, R56.8, G40, G41, M321, M328, M329, L930, L931, L932, E830  | 345, 695, 710 |
|  |  |  |

ICD-9: International Classification of Diseases, Ninth Revision, ICD-10: International Classification of Diseases, Tenth Revision; OHIP: Ontario Health Insurance Plan; a measured by presence in 365 days prior to index date minus 9 months